NASDAQ:VVUS - Vivus Stock Price, Price Target & More

$0.3851 -0.02 (-4.94 %)
(As of 04/22/2018 04:12 AM ET)
Previous Close$0.3851
Today's Range$0.3851 - $0.4227
52-Week Range$0.33 - $1.38
Volume276,681 shs
Average Volume419,966 shs
Market Capitalization$42.51 million
P/E Ratio-1.33
Dividend YieldN/A
Beta0.61

About Vivus (NASDAQ:VVUS)

Vivus logoVIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Receive VVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:VVUS
CUSIP92855110
Phone650-934-5200

Debt

Debt-to-Equity Ratio-24.71%
Current Ratio6.80%
Quick Ratio6.34%

Price-To-Earnings

Trailing P/E Ratio-1.33
Forward P/E Ratio-0.86
P/E GrowthN/A

Sales & Book Value

Annual Sales$65.37 million
Price / Sales0.62
Cash FlowN/A
Price / CashN/A
Book Value($0.09) per share
Price / Book-4.28

Profitability

EPS (Most Recent Fiscal Year)($0.29)
Net Income$-30,510,000.00
Net Margins-46.67%
Return on Equity-843.43%
Return on Assets-10.99%

Miscellaneous

Employees52
Outstanding Shares106,020,000

How to Become a New Pot Stock Millionaire

Vivus (NASDAQ:VVUS) Frequently Asked Questions

What is Vivus' stock symbol?

Vivus trades on the NASDAQ under the ticker symbol "VVUS."

How were Vivus' earnings last quarter?

Vivus (NASDAQ:VVUS) announced its quarterly earnings data on Tuesday, March, 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.04. The biopharmaceutical company earned $11.94 million during the quarter. Vivus had a negative return on equity of 843.43% and a negative net margin of 46.67%. View Vivus' Earnings History.

When is Vivus' next earnings date?

Vivus is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Vivus.

Who are some of Vivus' key competitors?

Who are Vivus' key executives?

Vivus' management team includes the folowing people:
  • Mr. Mark K. Oki, CFO & Chief Accounting Officer (Age 49)
  • Mr. John L. Slebir Esq., Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 53)
  • Dr. Santosh T. Varghese M.D., Chief Medical Officer (Age 48)
  • Mr. Seth H. Z. Fischer, Strategic Adviser (Age 62)
  • Mr. Thomas B. King, Interim CEO & Director (Age 63)

Has Vivus been receiving favorable news coverage?

Media headlines about VVUS stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vivus earned a news impact score of 0.07 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Vivus?

Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vivus' stock price today?

One share of VVUS stock can currently be purchased for approximately $0.3851.

How big of a company is Vivus?

Vivus has a market capitalization of $42.51 million and generates $65.37 million in revenue each year. The biopharmaceutical company earns $-30,510,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Vivus employs 52 workers across the globe.

How can I contact Vivus?

Vivus' mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]


MarketBeat Community Rating for Vivus (VVUS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  304 (Vote Underperform)
Total Votes:  554
MarketBeat's community ratings are surveys of what our community members think about Vivus and other stocks. Vote "Outperform" if you believe VVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vivus (NASDAQ:VVUS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Vivus (NASDAQ:VVUS) Consensus Price Target History

Price Target History for Vivus (NASDAQ:VVUS)

Vivus (NASDAQ:VVUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/25/2016WallachBeth CapitalSet Price TargetBuy$2.80N/AView Rating Details
5/4/2016JPMorgan ChaseReiterated RatingHoldN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Vivus (NASDAQ:VVUS) Earnings History and Estimates Chart

Earnings by Quarter for Vivus (NASDAQ:VVUS)

Vivus (NASDAQ:VVUS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS

Vivus (NASDAQ VVUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018($0.11)N/AView Earnings Details
3/13/2018Q4 2017($0.13)($0.0950)$11.94 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.13)($0.0570)$16.00 million$15.19 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.13)($0.13)$11.23 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.13)($0.01)$27.01 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.23$0.54$48.82 million$81.81 millionViewListenView Earnings Details
11/9/2016Q316($0.19)($0.09)$21.91 million$13.40 millionViewListenView Earnings Details
8/4/2016Q216($0.31)($0.11)$19.00 million$13.77 millionViewN/AView Earnings Details
5/3/2016Q116($0.21)($0.12)$17.97 million$15.32 millionViewN/AView Earnings Details
3/9/2016Q4($0.12)($0.12)$22.90 million$15.34 millionViewN/AView Earnings Details
11/4/2015Q315($0.17)($0.15)$20.24 million$24.90 millionViewN/AView Earnings Details
7/30/2015Q215($0.23)($0.19)$18.76 million$23.00 millionViewListenView Earnings Details
5/5/2015Q115($0.22)($0.15)$21.80 million$32.20 millionViewN/AView Earnings Details
2/24/2015Q414($0.25)($0.25)$20.00 million$21.70 millionViewListenView Earnings Details
11/5/2014Q314($0.25)($0.10)$21.90 million$33.90 millionViewListenView Earnings Details
8/7/2014Q214($0.28)($0.25)$17.90 million$21.90 millionViewListenView Earnings Details
5/5/2014Q114($0.37)($0.15)$11.40 million$36.70 millionViewN/AView Earnings Details
2/24/2014Q413($0.40)($0.17)$28.20 million$44.06 millionViewListenView Earnings Details
11/5/2013Q313($0.38)($0.48)$21.78 million$27.38 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.55)$12.76 million$5.53 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.51)($0.53)$5.22 million$4.10 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.44)($0.56)$3.09 million$1.97 millionViewN/AView Earnings Details
11/6/2012Q312($0.34)($0.40)$0.35 million$0.04 millionViewN/AView Earnings Details
8/7/2012($0.23)($0.24)ViewN/AView Earnings Details
5/7/2012($0.13)($0.20)ViewN/AView Earnings Details
2/28/2012($0.12)($0.14)ViewN/AView Earnings Details
11/7/2011($0.12)($0.10)ViewN/AView Earnings Details
8/1/2011($0.13)($0.20)ViewN/AView Earnings Details
5/2/2011($0.15)($0.12)ViewN/AView Earnings Details
2/28/2011($0.22)($0.23)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.27)($0.22)ViewN/AView Earnings Details
8/2/2010Q2 2010($0.23)($0.28)ViewN/AView Earnings Details
5/3/2010Q1 2010($0.26)($0.23)ViewN/AView Earnings Details
3/8/2010Q4 2009($0.25)($0.16)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.31)($0.30)ViewN/AView Earnings Details
8/11/2009Q2 2009($0.18)($0.19)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.08)($0.10)ViewN/AView Earnings Details
3/9/2009Q4 2008($0.05)ViewN/AView Earnings Details
8/4/2008Q2 2008($0.05)$0.06ViewN/AView Earnings Details
5/8/2008Q1 2008$0.08($0.12)ViewN/AView Earnings Details
3/6/2008Q4 2007$0.21$0.17ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Vivus (NASDAQ:VVUS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Vivus (NASDAQ VVUS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 24.82%
Insider Trading History for Vivus (NASDAQ:VVUS)
Institutional Ownership by Quarter for Vivus (NASDAQ:VVUS)

Vivus (NASDAQ VVUS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2018Santosh T VargheseInsiderSell390$0.34$132.60View SEC Filing  
1/31/2018Santosh T VargheseInsiderSell491$0.43$211.1371,805View SEC Filing  
1/1/2018Santosh T VargheseInsiderSell444$0.51$226.4472,296View SEC Filing  
10/3/2017Santosh T VargheseInsiderSell434$0.97$420.98View SEC Filing  
7/3/2017Santosh T VargheseInsiderSell423$1.23$520.2973,174View SEC Filing  
4/4/2017Santosh T VargheseInsiderSell440$1.08$475.2073,597View SEC Filing  
3/10/2017North Tide Capital, LlcMajor ShareholderSell1,149,400$1.16$1,333,304.00View SEC Filing  
3/7/2017North Tide Capital, LlcMajor ShareholderSell192,800$1.08$208,224.00View SEC Filing  
3/2/2017North Tide Capital, LlcMajor ShareholderSell160,100$1.13$180,913.00View SEC Filing  
2/27/2017North Tide Capital, LlcMajor ShareholderSell333,000$1.14$379,620.00View SEC Filing  
2/22/2017North Tide Capital, LlcMajor ShareholderSell161,800$1.11$179,598.00View SEC Filing  
2/16/2017North Tide Capital, LlcMajor ShareholderSell305,090$1.10$335,599.00View SEC Filing  
2/13/2017North Tide Capital, LlcMajor ShareholderSell176,410$1.11$195,815.10View SEC Filing  
2/8/2017North Tide Capital, LlcMajor ShareholderSell563,527$1.06$597,338.62View SEC Filing  
2/7/2017North Tide Capital, LlcMajor ShareholderSell6,200$1.11$6,882.00View SEC Filing  
2/6/2017North Tide Capital, LlcMajor ShareholderSell28,027$1.10$30,829.70View SEC Filing  
2/3/2017North Tide Capital, LlcMajor ShareholderSell78,633$1.12$88,068.96View SEC Filing  
1/28/2017Santosh T VargheseInsiderSell429$1.11$476.1974,037View SEC Filing  
12/31/2016Santosh T VargheseInsiderSell13,790$1.12$15,444.8074,830View SEC Filing  
10/1/2016Santosh T VargheseInsiderSell710$1.14$809.4088,610View SEC Filing  
8/2/2016Santosh T VargheseInsiderSell12,559$1.07$13,438.1388,966View SEC Filing  
7/1/2016Santosh T VargheseVPSell366$1.21$442.86101,525View SEC Filing  
4/7/2016Santosh T VargheseInsiderSell329$1.65$542.85101,891View SEC Filing  
4/1/2016North Tide Capital, LlcMajor ShareholderBuy2,160$1.40$3,024.00View SEC Filing  
3/31/2016North Tide Capital, LlcMajor ShareholderBuy383,300$1.29$494,457.00View SEC Filing  
3/28/2016North Tide Capital, LlcMajor ShareholderBuy202,000$1.12$226,240.00View SEC Filing  
3/16/2016North Tide Capital, LlcMajor ShareholderBuy500,000$1.21$605,000.00View SEC Filing  
1/1/2016John L SlebirSVPSell2,973$3.04$9,037.9244,555View SEC Filing  
1/8/2015North Tide Capital, LlcMajor ShareholderBuy500,000$3.12$1,560,000.00View SEC Filing  
1/6/2015North Tide Capital, LlcMajor ShareholderBuy476,800$3.04$1,449,472.00View SEC Filing  
1/2/2015North Tide Capital, LlcMajor ShareholderBuy523,200$2.90$1,517,280.00View SEC Filing  
3/11/2014Seth H.Z. FischerCEOBuy3,080$6.07$18,695.603,080View SEC Filing  
11/11/2013Alexander DennerDirectorBuy566,844$8.59$4,869,189.96View SEC Filing  
9/5/2013Timothy E MorrisCFOSell10,654$11.95$127,315.30View SEC Filing  
9/4/2013Michael J AstrueDirectorBuy10,000$11.96$119,600.00View SEC Filing  
6/27/2013Jon C BiroInsiderBuy2,000$12.85$25,700.00View SEC Filing  
5/29/2013Ernest MarioDirectorBuy15,000$14.68$220,200.00View SEC Filing  
8/20/2012Ernest MarioDirectorBuy5,000$20.75$103,750.00View SEC Filing  
8/10/2012Ernest MarioDirectorBuy20,000$21.74$434,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vivus (NASDAQ VVUS) News Headlines

Source:
DateHeadline
-$0.11 Earnings Per Share Expected for Vivus (VVUS) This Quarter-$0.11 Earnings Per Share Expected for Vivus (VVUS) This Quarter
www.americanbankingnews.com - April 17 at 3:06 AM
Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report?Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report?
finance.yahoo.com - April 12 at 10:39 AM
Quotidian Technical Highlights on Selected Biotech Stocks -- Vertex Pharma, VIVUS, Voyager Therapeutics, and ...Quotidian Technical Highlights on Selected Biotech Stocks -- Vertex Pharma, VIVUS, Voyager Therapeutics, and ...
www.prnewswire.com - April 10 at 4:13 PM
Vivus (VVUS) Lowered to Strong Sell at ValuEngineVivus (VVUS) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 2 at 10:23 PM
Zacks: Brokerages Anticipate VIVUS, Inc. (VVUS) to Announce -$0.11 Earnings Per ShareZacks: Brokerages Anticipate VIVUS, Inc. (VVUS) to Announce -$0.11 Earnings Per Share
www.americanbankingnews.com - March 31 at 8:32 AM
Novo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena FailedNovo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena Failed
seekingalpha.com - March 24 at 4:36 PM
BRIEF-Vivus Reports Qtrly ‍loss Per Share $0.10BRIEF-Vivus Reports Qtrly ‍loss Per Share $0.10
www.reuters.com - March 14 at 12:37 PM
VIVUS (VVUS) Issues  Earnings ResultsVIVUS (VVUS) Issues Earnings Results
www.americanbankingnews.com - March 14 at 12:20 PM
VIVUS Reports Fourth Quarter 2017 Financial ResultsVIVUS Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - March 13 at 4:28 PM
Vivus reports 4Q lossVivus reports 4Q loss
finance.yahoo.com - March 13 at 4:28 PM
VIVUS (VVUS) Scheduled to Post Quarterly Earnings on TuesdayVIVUS (VVUS) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:34 AM
 Brokerages Expect VIVUS, Inc. (VVUS) to Announce -$0.13 EPS Brokerages Expect VIVUS, Inc. (VVUS) to Announce -$0.13 EPS
www.americanbankingnews.com - February 25 at 5:20 AM
Kadmon (KDMN) and VIVUS (VVUS) Critical AnalysisKadmon (KDMN) and VIVUS (VVUS) Critical Analysis
www.americanbankingnews.com - February 20 at 4:31 PM
Head to Head Survey: Transition Therapeutics (TTHI) and VIVUS (VVUS)Head to Head Survey: Transition Therapeutics (TTHI) and VIVUS (VVUS)
www.americanbankingnews.com - February 10 at 7:14 PM
VIVUS (VVUS) Raised to Sell at ValuEngineVIVUS (VVUS) Raised to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 12:38 PM
Zacks: Analysts Anticipate VIVUS, Inc. (VVUS) to Announce -$0.13 EPSZacks: Analysts Anticipate VIVUS, Inc. (VVUS) to Announce -$0.13 EPS
www.americanbankingnews.com - January 22 at 11:30 AM
Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUSFree Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS
www.bizjournals.com - January 17 at 10:30 AM
VIVUS (VVUS) Rating Lowered to Hold at Zacks Investment ResearchVIVUS (VVUS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 6 at 1:16 PM
-$0.13 EPS Expected for VIVUS, Inc. (VVUS) This Quarter-$0.13 EPS Expected for VIVUS, Inc. (VVUS) This Quarter
www.americanbankingnews.com - January 5 at 11:36 AM
VIVUS (VVUS) Announces Thomas King as Interim CEO - StreetInsider.comVIVUS (VVUS) Announces Thomas King as Interim CEO - StreetInsider.com
www.streetinsider.com - December 27 at 6:16 PM
ETFs with exposure to VIVUS, Inc. : December 22, 2017ETFs with exposure to VIVUS, Inc. : December 22, 2017
finance.yahoo.com - December 22 at 6:25 PM
ETFs with exposure to VIVUS, Inc. : December 11, 2017ETFs with exposure to VIVUS, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 4:29 PM
Pre-Market Technical Scan on Biotech Equities -- Regeneron Pharma, Voyager Therapeutics, Five Prime Therapeutics ... - PR Newswire (press release)Pre-Market Technical Scan on Biotech Equities -- Regeneron Pharma, Voyager Therapeutics, Five Prime Therapeutics ... - PR Newswire (press release)
www.prnewswire.com - December 5 at 12:20 PM
VIVUS (VVUS) Rating Lowered to Strong Sell at ValuEngineVIVUS (VVUS) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - December 1 at 11:52 PM
ETFs with exposure to VIVUS, Inc. : November 20, 2017ETFs with exposure to VIVUS, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 4:02 PM
 Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - November 17 at 1:38 PM
ETFs with exposure to VIVUS, Inc. : November 10, 2017ETFs with exposure to VIVUS, Inc. : November 10, 2017
finance.yahoo.com - November 12 at 1:16 PM
Edited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 9:43 AM
VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 9 at 9:43 AM
VIVUS, Inc. (VVUS) Releases  Earnings Results, Beats Estimates By $0.07 EPSVIVUS, Inc. (VVUS) Releases Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - November 8 at 7:11 PM
Vivus reports 3Q lossVivus reports 3Q loss
finance.yahoo.com - November 7 at 6:25 PM
VIVUS Reports Third Quarter 2017 Financial ResultsVIVUS Reports Third Quarter 2017 Financial Results
feeds.benzinga.com - November 7 at 4:43 PM
VIVUS, Inc. to Host Earnings CallVIVUS, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 1:24 PM
VIVUS Completes Tacrolimus Pre-IND Meeting With FDAVIVUS Completes Tacrolimus Pre-IND Meeting With FDA
finance.yahoo.com - November 2 at 11:13 AM
ETFs with exposure to VIVUS, Inc. : October 30, 2017ETFs with exposure to VIVUS, Inc. : October 30, 2017
finance.yahoo.com - October 31 at 12:01 PM
VIVUS, Inc. (VVUS) Set to Announce Quarterly Earnings on TuesdayVIVUS, Inc. (VVUS) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:52 AM
VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017
feeds.benzinga.com - October 31 at 8:50 AM
ETFs with exposure to VIVUS, Inc. : October 20, 2017ETFs with exposure to VIVUS, Inc. : October 20, 2017
finance.yahoo.com - October 20 at 4:34 PM
Financial Review: VIVUS (VVUS) vs. The CompetitionFinancial Review: VIVUS (VVUS) vs. The Competition
www.americanbankingnews.com - October 17 at 8:26 AM
VIVUS (VVUS) and Sinovac Biotech (SVA) Head to Head ReviewVIVUS (VVUS) and Sinovac Biotech (SVA) Head to Head Review
www.americanbankingnews.com - October 12 at 10:32 PM
ETFs with exposure to VIVUS, Inc. : October 9, 2017ETFs with exposure to VIVUS, Inc. : October 9, 2017
finance.yahoo.com - October 10 at 8:14 AM
Critical Contrast: VIVUS (VVUS) versus Its PeersCritical Contrast: VIVUS (VVUS) versus Its Peers
www.americanbankingnews.com - October 9 at 6:28 PM
VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 12:42 PM
Argos Therapeutics (ARGS) & VIVUS (VVUS) Head-To-Head SurveyArgos Therapeutics (ARGS) & VIVUS (VVUS) Head-To-Head Survey
www.americanbankingnews.com - September 29 at 12:34 PM
Orexigens (OREX) Contrave Sales Improving on PromotionsOrexigen's (OREX) Contrave Sales Improving on Promotions
www.zacks.com - September 28 at 10:20 AM
Critical Survey: VIVUS (VVUS) versus Its RivalsCritical Survey: VIVUS (VVUS) versus Its Rivals
www.americanbankingnews.com - September 18 at 2:26 AM
VIVUS, Inc. (VVUS) Sees Large Drop in Short InterestVIVUS, Inc. (VVUS) Sees Large Drop in Short Interest
www.americanbankingnews.com - September 15 at 1:28 AM
VIVUS (VVUS) Says Tacrolimus Received Orphan Drug Designation in the European Union for the Treatment of PAHVIVUS (VVUS) Says Tacrolimus Received Orphan Drug Designation in the European Union for the Treatment of PAH
www.streetinsider.com - September 8 at 10:10 AM
VIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline AnalysisVIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis
finance.yahoo.com - September 8 at 10:10 AM
VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial HypertensionVIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
finance.yahoo.com - September 7 at 11:05 AM

SEC Filings

Vivus (NASDAQ:VVUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vivus (NASDAQ:VVUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vivus (NASDAQ VVUS) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.